Tracking when private companies are nearing a sale, recap, or financing event has always been a guessing game. With thousands of sponsor-backed firms spread across sectors and geographies, most deal teams are forced to react after the market moves.
Investors, bankers, and service providers struggle to know which private companies are gearing up for a transaction or capital raise. Signals are scattered, opaque, and nearly impossible to track across thousands of PE- and VC-backed businesses.
Dakota centralizes those signals (holding periods, funding rounds, platform acquisition dates, ownership changes, and exit timing patterns) into one predictive transaction-readiness tool. Instead of waiting for headlines, users can see which companies are showing the strongest likelihood of pursuing a sale, recapitalization, or new financing before the market knows.
Below is today’s list of five PE- or VC-backed companies that, based on their hold period, financing stage, and last transaction date, appear to be credible candidates for a sale or next-round raise.
Nothing is guaranteed, but these companies fall squarely within the timing windows where sponsors typically look to generate liquidity or secure additional capital.
Sourced from Dakota Sponsor Backed Companies.
1. Clarium
Clarium is a healthcare technology company specializing in AI-powered supply chain management solutions. Their platform, Astra OS, integrates data from hospitals and suppliers to enhance efficiency, visibility, and resiliency in healthcare supply chains. Key applications include disruption monitoring, substitute management, and procedure card optimization.
- Sector: Health Care
- Last known transaction date: Series A Venture, $27M, May 2025
- Why timing suggests a near-term transaction: A $27M Series A in May 2025 provides a solid 18–24 month runway for a healthcare company, but clinical development timelines and regulatory milestones in the sector tend to drive capital needs sooner than expected — positioning Clarium for a Series B raise by late 2026 to early 2027 as data readouts and product or platform validation from the Series A period create the proof points needed to support a larger growth-stage round.
View all private company data in Dakota Marketplace.
2. Pathex
PATH EX, Inc. is a privately held medical device company headquartered in Houston, Texas, specializing in the development of innovative technologies for the rapid diagnosis and treatment of sepsis. Their flagship product, CycloPE®, is designed to directly capture and remove bacteria from the bloodstream, offering a targeted solution to combat life-threatening infections. The company aims to revolutionize sepsis care and improve patient survival rates.
- Sector: Health Care
- Last known transaction date: Series A Venture, $5M, May 2025
- Why timing suggests a near-term transaction: A $5M Series A in May 2025 is a lean raise for a healthcare company where regulatory, clinical, and commercialization costs are elevated, providing a tight runway of 12–18 months — placing Pathex squarely in the active fundraising window for a Series B by late 2026 as it looks to advance key milestones and secure the additional capital needed to sustain development momentum.
View all private company data in Dakota Marketplace.
3. Rainmaker
Rainmaker Technology is a company specializing in precipitation enhancement technology, utilizing cloud seeding to increase rainfall and address water scarcity issues. Their services support agriculture, water utilities, and ecosystem restoration by generating additional freshwater resources.
- Sector: Consumer Staples
- Last known funding round: Series A Venture, $25M, May 2025
- Why timing suggests a near-term transaction: A $25M Series A in May 2025 provides a consumer staples company with roughly 18–24 months of runway, with capital typically deployed toward supply chain buildout, retail distribution, and brand development — positioning Rainmaker for a Series B raise by late 2026 to early 2027 as it looks to demonstrate the revenue scale, repeat purchase metrics, and retail penetration that growth-stage investors expect before committing larger capital.
View all private company data in Dakota Marketplace.
4. Scalera
Scalera is an AI-powered platform designed to automate and optimize the administrative processes involved in construction procurement and tendering. By leveraging artificial intelligence, Scalera aims to streamline the creation of offers from specifications and bills of quantities, enabling construction companies to efficiently generate more profitable bids and increase revenue.
- Sector: SaaS
- Last known funding round: Seed Venture, $6.5M, May 2025
- Why timing suggests a near-term transaction: A $6.5M seed round in May 2025 provides roughly 12–18 months of runway for an IT company, placing Scalera in the active fundraising window for a Series A by late 2026 as it works to convert early product development into demonstrable customer traction, recurring revenue signals, and the growth metrics that institutional Series A investors require to underwrite a larger round.
View all private company data in Dakota Marketplace.
5. Vicora
Vicora is a medical device company headquartered in Buffalo, New York, specializing in the development of innovative thrombectomy solutions. The company is dedicated to advancing the treatment of venous thromboembolism by introducing the world's first catheter with an integrated distal tip vibration, aiming to enhance clot removal efficiency. Vicora operates under the umbrella of Egret Healthcare Ventures, a firm focused on fostering medical device innovation. The leadership team includes Shawn Patterson as CEO, Rick Ducharme as Chief Scientific Officer, and Bill Maggio as Executive Chairman. The company's strategic objectives involve leveraging cutting-edge technology to improve patient outcomes in thrombectomy procedures.
- Sector: Health Care
- Last known funding round: Seed Venture, Undisclosed, May 2025
- Why timing suggests a near-term transaction: An undisclosed seed round in May 2025 for a healthcare company typically implies a raise in the $1–5M range, providing a lean 12–18 month runway given the sector's elevated regulatory and development costs — placing Vicora in the active fundraising window for a Series A by late 2026 as early preclinical, product, or platform milestones from the seed period provide the proof points needed to attract institutional capital.
View all private company data in Dakota Marketplace.
Use Dakota’s Sponsor Backed Company Intelligence to Spot Likely Exits Before the Market Does
Dakota’s private company data gives you a real-time view into thousands of sponsor-backed companies, including platform acquisition dates, funding rounds, parent sponsors, add-on activity, and sector categorization.
Instead of guessing where companies are in their lifecycle, you can instantly identify which ones are approaching the typical timing windows for a sale or recap.
Fully integrated into Dakota Marketplace, this dataset enables deal sourcers, investor relations teams, and allocators to anticipate transactions, build targeted outreach lists, and stay ahead of market announcements, every single day.
To explore more companies likely to transact, book a demo of Dakota Marketplace!
